<?xml version="1.0" encoding="UTF-8"?>
<p>Studies of the complex of double-stranded polyriboguanylic and polyribocytidylic acids (PolyG:PolyC, Polyguacyl) performed in the 1970sâ€“1980s, showed that the drug had a broad spectrum of antiviral activity and could be effective in the acute phase of viral hepatitis and encephalitis, for the treatment of influenza and rabies [
 <xref ref-type="bibr" rid="CR61">61</xref>, 
 <xref ref-type="bibr" rid="CR66">66</xref>]. However, a number of significant drawbacks, such as the uncertainty of the chemical structure, the lack of homogeneity and, as a result, the unpredictable pharmacokinetics and toxicity of Polyguacyl became a serious obstacle to its clinical use [
 <xref ref-type="bibr" rid="CR46">46</xref>, 
 <xref ref-type="bibr" rid="CR67">67</xref>].
</p>
